Jiangsu Hengrui Medicine Co., Ltd.
600276.SS

$44.02 B
Marketcap
$6.93
Share price
Country
$-0.04
Change (1 day)
$7.95
Year High
$4.91
Year Low

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

marketcap

Earnings for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Earnings in 2023 (TTM): $644.73 M

According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports the company's current earnings (TTM) are $644.73 M. The earnings displayed on this page is the company's Pretax Income.

Earnings history of Jiangsu Hengrui Medicine Co., Ltd.

Annual Earnings

Year Income Before Tax Net Income
2023 $644.73 M $594.35 M
2022 $548.22 M $539.64 M
2021 $616.99 M $625.82 M
2020 $952.56 M $874.22 M
2019 $836.56 M $736.03 M
2018 $621.52 M $561.64 M
2017 $519.31 M $444.36 M
2016 $416.25 M $357.65 M
2015 $353.92 M $299.99 M
2014 $248.61 M $209.37 M
2013 $204.25 M $171.04 M
2012 $186.01 M $148.83 M
2011 $147.13 M $121.1 M
2010 $118.83 M $100.04 M
2009 $107.85 M $91.97 M
2008 $64.93 M $58.43 M
2007 $70.65 M $57.04 M
2006 $39.96 M $28.55 M
2005 $30.49 M $22.41 M
2004 $23.85 M $16.94 M
2003 $20.82 M $13.06 M
2002 $15.27 M $10.91 M
2001 $13.49 M $11.21 M
2000 $11.31 M $9.02 M
1999 $8.66 M $7.09 M
1998 $7.2 M $5.97 M
1997 $6.15 M $5.67 M